Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
$0.02
$0.01
$3.75
$804K-1.12790,280 shs740,620 shs
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$9.25
$9.22
$3.46
$9.28
$420.52M1.3840,890 shs178,496 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$6.17
-3.7%
$6.60
$3.04
$8.69
$79.40M0.7834,696 shs18,252 shs
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$1.36
-1.4%
$1.44
$0.88
$4.30
$32.91M1.3462,828 shs20,236 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
-19.25%-16.08%-19.75%-56.91%-99.55%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.00%0.00%0.00%0.00%0.00%
LifeVantage Co. stock logo
LFVN
LifeVantage
+5.87%+2.32%-7.17%+14.99%+89.30%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
+0.75%+4.69%+5.51%-9.46%-64.52%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
2.9891 of 5 stars
0.05.01.72.73.11.71.3
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
2.00
HoldN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
N/AN/AN/AN/A
Theratechnologies Inc. stock logo
THTX
Theratechnologies
3.00
BuyN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$18.22M0.04$1.49 per share0.01($2.64) per share-0.01
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$42.16M9.97N/AN/A$1.75 per share5.29
LifeVantage Co. stock logo
LFVN
LifeVantage
$210.95M0.38$0.53 per share11.67$2.71 per share2.28
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$81.76M0.40N/AN/A($1.02) per share-1.33

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$7.62N/AN/A290.81%-90.20%331.20%4/26/2024 (Estimated)
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.54M$0.2326.83N/A1.40%19.96%9.48%5/2/2024 (Confirmed)
Theratechnologies Inc. stock logo
THTX
Theratechnologies
-$23.96M-$0.61N/A19.43N/A-23.04%N/A-26.15%7/10/2024 (Estimated)

Latest EVFM, KIN, THTX, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
LifeVantage Co. stock logo
LFVN
LifeVantage
N/AN/AN/AN/AN/AN/A  
3/27/2024Q4 2023
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A-$0.44-$0.44-$0.44N/A$4.84 million
2/21/202411/30/2023
Theratechnologies Inc. stock logo
THTX
Theratechnologies
-$0.24-$0.08+$0.16-$0.08N/A$23.45 million
1/30/2024Q2 2024
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A$0.10+$0.10$0.25N/A$51.62 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.142.27%N/A60.87%1 Years
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/AN/AN/AN/AN/A

Latest EVFM, KIN, THTX, and LFVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/25/2024
LifeVantage Co. stock logo
LFVN
LifeVantage
Quarterly$0.03502.64%2/29/20243/1/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.13
0.10
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.19
7.02
7.02
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.68
1.03
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A
1.15
1.03

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
66.89%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A

Insider Ownership

CompanyInsider Ownership
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.21%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
13.69%
LifeVantage Co. stock logo
LFVN
LifeVantage
6.76%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
3553.96 million53.85 millionNot Optionable
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
6345.46 millionN/AOptionable
LifeVantage Co. stock logo
LFVN
LifeVantage
24812.87 million12.00 millionOptionable
Theratechnologies Inc. stock logo
THTX
Theratechnologies
10324.20 millionN/AOptionable

EVFM, KIN, THTX, and LFVN Headlines

SourceHeadline
Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com - April 23 at 1:00 PM
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of ShareholdersTheratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
globenewswire.com - April 15 at 4:15 PM
FY2024 Earnings Estimate for Theratechnologies Inc. Issued By Cantor Fitzgerald (NASDAQ:THTX)FY2024 Earnings Estimate for Theratechnologies Inc. Issued By Cantor Fitzgerald (NASDAQ:THTX)
americanbankingnews.com - April 15 at 1:34 AM
Theratechnologies Inc. (THTX) Q1 2024 Earnings Call TranscriptTheratechnologies Inc. (THTX) Q1 2024 Earnings Call Transcript
seekingalpha.com - April 11 at 10:34 PM
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceTheratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
globenewswire.com - April 11 at 7:30 AM
THTX Stock Earnings: Theratechnologies Beats EPS, Misses Revenue for Q1 2024THTX Stock Earnings: Theratechnologies Beats EPS, Misses Revenue for Q1 2024
investorplace.com - April 10 at 1:04 PM
Theratechnologies: Fiscal Q1 Earnings SnapshotTheratechnologies: Fiscal Q1 Earnings Snapshot
timesunion.com - April 10 at 8:55 AM
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
globenewswire.com - April 10 at 7:30 AM
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
globenewswire.com - April 10 at 7:30 AM
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology PlatformTheratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
globenewswire.com - April 8 at 4:30 PM
Theratechnologies Appoints Elina Tea to its Board of DirectorsTheratechnologies Appoints Elina Tea to its Board of Directors
globenewswire.com - April 5 at 11:00 AM
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business UpdateTheratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
globenewswire.com - April 3 at 7:30 AM
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology(TM) PlatformTheratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology(TM) Platform
stockhouse.com - March 30 at 4:15 PM
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ PlatformTheratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
globenewswire.com - March 28 at 7:30 AM
Theratechnologies shifts focus, phases down preclinical researchTheratechnologies shifts focus, phases down preclinical research
investing.com - March 24 at 9:04 PM
Theratechnologies Announces Update on its Preclinical Oncology Research ProgramTheratechnologies Announces Update on its Preclinical Oncology Research Program
globenewswire.com - March 22 at 9:36 AM
Theratechnologies Appoints Jordan Zwick to its Board of DirectorsTheratechnologies Appoints Jordan Zwick to its Board of Directors
globenewswire.com - March 21 at 8:00 PM
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerTheratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
globenewswire.com - March 21 at 7:30 AM
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain TrudeauTheratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
globenewswire.com - February 29 at 4:34 PM
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDATheratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
globenewswire.com - February 27 at 7:30 AM
Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain StockTheratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain Stock
zacks.com - February 26 at 9:51 AM
THTX stock keeps “Buy” rating at Research CapitalTHTX stock keeps “Buy” rating at Research Capital
cantechletter.com - February 21 at 4:53 PM
Theratechnologies: Fiscal Q4 Earnings SnapshotTheratechnologies: Fiscal Q4 Earnings Snapshot
washingtonpost.com - February 21 at 11:52 AM
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 GuidanceTheratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
globenewswire.com - February 21 at 7:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Evofem Biosciences logo

Evofem Biosciences

NASDAQ:EVFM
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Kindred Biosciences logo

Kindred Biosciences

NASDAQ:KIN
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.
LifeVantage logo

LifeVantage

NASDAQ:LFVN
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.
Theratechnologies logo

Theratechnologies

NASDAQ:THTX
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.